BAP31 deficiency exacerbates α-synucleinopathy-associated neurodegeneration by disrupting mitochondrial fission–fusion dynamics, impairing PINK1–Parkin-mediated, amplifying dopaminergic neuron loss. Here, PRKN is linked to synucleinopathy.